MER 5101
Alternative Names: Alzheimer's Disease Vaccine - Mercia Pharma; MER5101Latest Information Update: 28 Jan 2019
At a glance
- Originator Mercia Pharma Inc
- Class Alzheimer vaccines; Antidementias; Protein vaccines
- Mechanism of Action Amyloid beta-protein modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA
- 08 Dec 2015 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)